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Clinical PerspectiveWhat Is New?In this large cohort study, we described a distinct genetic spectrum in Chinese patients with left ventricular noncompaction cardiomyopathy.More than one third of the patients carried at least one pathogenic variant, with *TTN*,*MYH7*,*MYBPC3*, and *DSP* being the most commonly involved genes.Genotype‐positive status was independently associated with increased risk of death and heart transplantation in adult patients.What Are the Clinical Implications?In the context of left ventricular noncompaction cardiomyopathy, genetic testing has a considerable yield in Chinese patients, as previously described in patients of European ancestry.Genetic testing is important for better risk stratification of the individual patient and should be recommended in clinical practice.

Introduction {#jah33489-sec-0008}
============

Left ventricular noncompaction cardiomyopathy (LVNC) is a genetically and clinically heterogeneous myocardial disorder that is present in 3% to 4% of patients with heart failure (HF).[1](#jah33489-bib-0001){ref-type="ref"}, [2](#jah33489-bib-0002){ref-type="ref"} It is characterized by a prominent trabecular meshwork and deep intertrabecular recesses communicating with the left ventricular cavity, morphologically reminiscent of early cardiac development.[3](#jah33489-bib-0003){ref-type="ref"}, [4](#jah33489-bib-0004){ref-type="ref"} The genesis of LVNC is generally thought to be caused by the arrest of myocardial compaction during the normal development of the heart.[5](#jah33489-bib-0005){ref-type="ref"}, [6](#jah33489-bib-0006){ref-type="ref"} Patients with LVNC show a wide spectrum of clinical presentations, ranging from no symptoms to thromboembolic events, end‐stage HF, or sudden cardiac death (SCD).[7](#jah33489-bib-0007){ref-type="ref"}, [8](#jah33489-bib-0008){ref-type="ref"}, [9](#jah33489-bib-0009){ref-type="ref"}, [10](#jah33489-bib-0010){ref-type="ref"}

LVNC was classified as a genetic cardiomyopathy by the American Heart Association,[11](#jah33489-bib-0011){ref-type="ref"} and genetics plays an important role in it. Genetic defects are found in 35% to 40% of patients with isolated LVNC by molecular testing, with *MYH7* as the most commonly involved gene.[12](#jah33489-bib-0012){ref-type="ref"}, [13](#jah33489-bib-0013){ref-type="ref"} Genes associated with LVNC usually include those encoding sarcomeric, cytoskeletal, or ion channel proteins, and those involved in cellular energy metabolism.[4](#jah33489-bib-0004){ref-type="ref"}

Although LVNC has been studied for nearly a century since it was first described in 1926,[14](#jah33489-bib-0014){ref-type="ref"} there is still a lot to be clarified about its genetic basis and genotype‐phenotype correlations. Thus, the current study aims to investigate the molecular defects, clinical manifestations, and long‐term outcomes, as well as the relationships among them, in a cohort of Chinese patients with LVNC.

Methods {#jah33489-sec-0009}
=======

Because of privacy, the data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.

Study Subjects {#jah33489-sec-0010}
--------------

A total of 100 unrelated patients with LVNC enrolled at Fuwai Hospital between April 2004 and May 2016 were included in the study. LVNC was diagnosed on the basis of established criteria from echocardiography and/or cardiac magnetic resonance.[15](#jah33489-bib-0015){ref-type="ref"}, [16](#jah33489-bib-0016){ref-type="ref"} The core item of these criteria is the ratio of the thickness of noncompacted/compact epicardial layer, which is \>2.0 measured on echocardiography in systole or \>2.3 on cardiac magnetic resonance in diastole. According to the age of onset, patients were divided into children (\<18 years) and adults (≥18 years). Demographic and clinical data of all participants were collected.

The study complies with the principles of the Declaration of Helsinki and was approved by the Ethics Committee of Fuwai Hospital. Written informed consent was obtained from each participant.

Targeted Sequencing {#jah33489-sec-0011}
-------------------

Genomic DNA was isolated from peripheral venous blood of each participant. The coding exons and their splicing regions (adjacent 10‐bp intronic sequences) of 72 cardiomyopathy‐related genes were enriched, as determined using a custom‐designed library (Agilent Technologies, Santa Clara, CA), and were subsequently sequenced on an Illumina next‐generation sequencing platform (Illumina Inc, San Diego, CA). Sequencing reads of each individual were mapped to the human reference genome with BWA (0.7.12). After removal of polymerase chain reaction duplications with PICARD, variants were called with GATK, version 3.5, and annotated by using ANNOVAR. The mean depths of the samples were \>400×, with coverage of \>99.7%. Details about the genes being tested are described in Data [S1](#jah33489-sup-0001){ref-type="supplementary-material"}.

Variants were described in accordance with the guidelines for mutation nomenclature of the Human Genome Variation Society (<http://www.hgvs.org/>). Variants were considered as polymorphisms and excluded if their minor allele frequency was ≥0.05% among East Asians in the Genome Aggregation Database.[17](#jah33489-bib-0017){ref-type="ref"} The pathogenicity of detected variants was determined in accordance with the recommendations of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology, and was classified as "pathogenic," "likely pathogenic," "uncertain significance," "likely benign," or "benign."[18](#jah33489-bib-0018){ref-type="ref"} Criteria for classification are listed in Table [S1](#jah33489-sup-0001){ref-type="supplementary-material"} and [S2](#jah33489-sup-0001){ref-type="supplementary-material"}. Variants classified as pathogenic or likely pathogenic were considered to be pathogenic in the current analysis. Patients with or without pathogenic variants were defined as genotype positive (G+) or genotype negative (G−), respectively. Sanger sequencing was used to validate the presence of pathogenic variants. The primers for the sequencing are listed in Table [S3](#jah33489-sup-0001){ref-type="supplementary-material"}.

Follow‐Up and End Points {#jah33489-sec-0012}
------------------------

Follow‐up data were obtained by telephone interview or clinic visit. The last follow‐up was performed in April 2018. The primary end point was a composite of death and heart transplantation (HT). The secondary end points included all‐cause death, HT, and cardiovascular death, which included SCD, HF‐related death, and death from other cardiovascular causes. SCD was defined as witnessed sudden death with or without documented ventricular fibrillation, death within 1 hour of new symptoms, or nocturnal deaths with no antecedent history of worsening symptoms. HF‐related death was defined as death preceded by symptoms of HF lasting \>1 hour.

Statistical Analysis {#jah33489-sec-0013}
--------------------

Continuous variables are expressed as median (interquartile range) and were compared by independent‐sample *t* test or Mann‐Whitney *U* test for abnormally distributed variables. Categorical variables are presented as proportions (%) and were compared using Pearson\'s χ^2^ test or Fisher\'s exact test. Univariable or multivariable Cox proportional hazards models were performed to calculate the hazard ratio and 95% confidence interval to estimate the effect of pathogenic variants on phenotypes. Survival curves were constructed in accordance with the Kaplan‐Meier method, and were compared using the log‐rank test. Factors included in the multivariate models for the outcomes were age, sex, and New York Heart Association functional class III/IV at baseline. Differences were considered significant if the 2‐sided *P* value was \<0.05. All analyses were performed with SPSS, version 22.0 software (IBM, Armonk, NY).

Results {#jah33489-sec-0014}
=======

Study Population and Genetic Profile {#jah33489-sec-0015}
------------------------------------

The participants in this study consisted of 17 children (17%) and 83 adults (83%). A total of 72 (72%) of them were male, with a median (interquartile range) age of 42 (24--53) years. A total of 42 pathogenic variants were found in 38 (38.0%) of patients, of which 29 (69.0%) of variants were located in sarcomere genes (Table [S4](#jah33489-sup-0001){ref-type="supplementary-material"}). Among these sarcomere genes, *TTN* was the most commonly involved gene (51.7%), followed by *MYH7* (17.2%), *MYBPC3* (13.8%), and *ACTC1* (6.9%) (Figure [1](#jah33489-fig-0001){ref-type="fig"}A). Eight nonsarcomere genes were detected with pathogenic variants, among which *DSP* (23.1%) was the most commonly mutated gene, followed by *DMD* (15.4%), *LAMP2* (15.4%), and *SCN5A* (15.4%). Notably, 25 (59.5%) of detected variants were novel, which were located in *TTN*,*MYBPC3*,*DSP*,*NNT*,*DMD*, and *LAMP2*.

![Spectrum of pathogenic variants in Chinese patients with left ventricular noncompaction cardiomyopathy. Panels show the variant spectrum in whole cohort (A), child patients (B) and adult patients (C).](JAH3-7-e009910-g001){#jah33489-fig-0001}

There was no significant difference in the proportions of G+ status between children (35.3%, 6/17) and adults (38.6%, 32/83; *P*=0.801). The proportions of variants in sarcomere genes were not significantly different between children and adults (42.9% and 72.2%, respectively; *P*=0.190), with *TTN* being the predominant gene in both groups (Figure [1](#jah33489-fig-0001){ref-type="fig"}B and [1](#jah33489-fig-0001){ref-type="fig"}C). Nonsarcomere genes accounted for 57.1% and 27.8% of the variants detected in children and adults, respectively.

Genotype‐Phenotype Correlation at Baseline {#jah33489-sec-0016}
------------------------------------------

Demographic and clinical characteristics of the participants are shown in Table [1](#jah33489-tbl-0001){ref-type="table"}. Similar characteristics were observed between G+ and G− children. For adults, atrial fibrillation and a family history of cardiomyopathy were more common; left ventricular ejection fraction was lower in G+ patients, whereas G− patients were more likely to have hypertension. Notably, 6 carriers of pathogenic variants in *DSP* were all found to have ventricular arrythmias (Table [S5](#jah33489-sup-0001){ref-type="supplementary-material"}).

###### 

Baseline Characteristics of G+ and G− Among Children and Adults

  Characteristics                           Children (n=17)     Adults (n=83)                                                       
  ----------------------------------------- ------------------- ------------------- ------- ------------------- ------------------- -------
  Age at enrollment, y                      16.0 (13.0--18.0)   14.0 (8.0--15.0)    0.149   44.0 (35.5--49.0)   46.0 (30.0--57.0)   0.506
  Age of onset, y                           15.5 (10.5--17.0)   13.0 (8.0--15.0)    0.180   39.5 (30.3--45.5)   42.0 (28.0--52.0)   0.660
  Male sex, n (%)                           6 (100.0)           8 (72.7)            0.515   22 (68.8)           36 (70.6)           0.859
  Family history of cardiomyopathy, n (%)   1 (16.7)            1 (9.1)             1.000   9 (28.1)            2 (3.9)             0.002
  NYHA class III/IV, n (%)                  3 (50.0)            1 (9.1)             0.099   17 (53.1)           22 (43.1)           0.375
  Comorbidities, n (%)                                                                                                              
  Coronary artery disease                   0 (0.0)             0 (0.0)             ···     1 (3.1)             8 (15.7)            0.143
  Hypertension                              0 (0.0)             1 (9.1)             1.000   0 (0.0)             13 (25.5)           0.001
  Diabetes mellitus                         0 (0.0)             0 (0.0)             ···     3 (9.4)             4 (7.8)             1.000
  Hyperlipidemia                            0 (0.0)             1 (9.1)             1.000   6 (18.8)            8 (15.7)            0.717
  Other cardiomyopathies                    3 (50.0)            3 (27.3)            0.600   11 (34.4)           10 (19.6)           0.132
  Atrial fibrillation                       0 (0.0)             0 (0.0)             ···     11 (34.4)           4 (7.8)             0.002
  Echocardiography                                                                                                                  
  LVEDD, mm                                 59.0 (50.0--69.8)   47.0 (37.0--69.0)   0.350   64.5 (52.3--70.0)   61.0 (54.8--70.0)   0.581
  LAD, mm                                   42.0 (30.3--50.5)   33.0 (27.0--36.0)   0.078   43.5 (36.8--50.0)   40.0 (34.0--46.5)   0.098
  LVEF, %                                   34.0 (20.3--61.3)   61.0 (25.0--69.0)   0.180   31.6 (25.5--44.8)   40.0 (33.0--56.8)   0.016

Data are given as median (interquartile range) unless otherwise indicated. G+ indicates genotype positive; G−, genotype negative; LAD, left atrial diameter; LVEDD, left ventricular end‐diastolic dimension; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.

Genotype‐Phenotype Correlation for Clinical Outcomes {#jah33489-sec-0017}
----------------------------------------------------

During a median (interquartile range) follow‐up of 4.5 (2.9--6.2) years, 32 patients (32.0%) reached the primary end point, of which 27 (27.0%) experienced death and 5 (5.0%) underwent HT. All deaths were attributable to cardiovascular causes, consisting of 20 HF‐related deaths, 6 SCDs, and 1 death attributable to another cardiovascular cause (Table [2](#jah33489-tbl-0002){ref-type="table"}).

###### 

Incidence of Primary and Secondary End Points in G+ and G− Patients

  End Point                         All Patients (n=100)   Child Patients   Adult Patients                                   
  --------------------------------- ---------------------- ---------------- ---------------- ------- ----------- ----------- -------
  Primary                                                                                                                    
  Death and heart transplantation   32 (32.0)              2 (33.3)         2 (18.2)         0.584   16 (50.0)   12 (23.5)   0.013
  Secondary                                                                                                                  
  All‐cause death                   27 (27.0)              1 (16.7)         2 (18.2)         1.000   12 (37.5)   12 (23.5)   0.172
  Heart transplantation             5 (5.0)                1 (16.7)         0 (0.0)          0.353   4 (12.5)    0 (0.0)     0.020
  Cardiovascular death              27 (27.0)              1 (16.7)         2 (18.2)         1.000   12 (37.5)   12 (23.5)   0.172
  Sudden cardiac death              6 (6.0)                0 (0.0)          2 (18.2)         0.515   1 (3.1)     3 (5.9)     1.000
  Heart failure--related death      20 (20.0)              1 (16.7)         0 (0.0)          0.353   11 (34.4)   8 (15.7)    0.049

Data are given as number (percentage). G+ indicates genotype positive; G−, genotype negative.

Of the 17 children, 4 (23.5%) reached the primary end point, of whom 2 (50.0%) were G+ (Table [S6](#jah33489-sup-0001){ref-type="supplementary-material"}). There was no significant difference in terms of the incidence of primary or secondary outcomes between G+ and G− patients (Table [2](#jah33489-tbl-0002){ref-type="table"}). Figure [2](#jah33489-fig-0002){ref-type="fig"}A displays the event‐free survival curve, demonstrating no difference in the risk of the primary end point.

![Survival curves free from death and heart transplantation in child patients (A) and adult patients (B) with left ventricular noncompaction cardiomyopathy. G+ indicates genotype positive; G−, genotype negative.](JAH3-7-e009910-g002){#jah33489-fig-0002}

For the 83 adults, 28 (33.7%) experienced the primary end point. There was no significant difference in the incidence of the primary or secondary end points between children and adults (*P*=0.411, Table [S7](#jah33489-sup-0001){ref-type="supplementary-material"}). G+ status was significantly more common in patients who reached the primary end point (57.1%, 16/28) than in those who did not (29.1%, 16/55; *P*=0.013; Table [S8](#jah33489-sup-0001){ref-type="supplementary-material"}). Significantly more cases of the primary end point, HT, and HF‐related death occurred in G+ patients than in G− patients (Table [2](#jah33489-tbl-0002){ref-type="table"}). No difference in incidence was observed between G+ and G− patients for the other end points. Multivariable Cox regression analyses showed that G+ status and New York Heart Association class III/IV at baseline were independently associated with an increased risk of the primary end point (hazard ratio, 2.49; 95% confidence interval, 1.15--5.37; *P*=0.020; and hazard ratio, 2.62; 95% confidence interval, 1.13--6.08; *P*=0.025, respectively) (Table [3](#jah33489-tbl-0003){ref-type="table"}). The event‐free survival curve is displayed in Figure [2](#jah33489-fig-0002){ref-type="fig"}B. In addition, G+ status was associated with an increased risk of HF‐related death in univariable analyses (Table [4](#jah33489-tbl-0004){ref-type="table"}). After adjustment, however, this association was no longer significant. No association between G+ status and other end points was observed.

###### 

Multivariable Analysis of Predictors of Primary End Points

  Variable            Univariable   Multivariable                               
  ------------------- ------------- --------------- ------- ------ ------------ -------
  G+ status           2.62          1.23--5.54      0.012   2.49   1.15--5.37   0.020
  Male sex            1.09          0.48--2.47      0.841   1.14   0.50--2.59   0.756
  Age                 1.01          0.99--1.03      0.461   1.01   0.98--1.04   0.629
  NYHA class III/IV   2.93          1.29--6.68      0.010   2.62   1.13--6.08   0.025

CI indicates confidence interval; G+, genotype positive; HR, hazard ratio; NYHA, New York Heart Association.

###### 

Univariable and Multivariable Analyses of G+ Status and Secondary End Points

  Variable                       Univariable                                 Multivariable[a](#jah33489-note-0007){ref-type="fn"}                               
  ------------------------------ ------------------------------------------- ------------------------------------------------------ ------- ------ ------------ -------
  All‐cause death                1.97                                        0.88--4.39                                             0.099   ···    ···          ···
  Heart transplantation          NA[b](#jah33489-note-0008){ref-type="fn"}   NA                                                     NA      ···    ···          ···
  Cardiovascular death           1.97                                        0.88--4.39                                             0.099   ···    ···          ···
  Sudden cardiac death           0.62                                        0.06--5.92                                             0.674   ···    ···          ···
  Heart failure--related death   2.77                                        1.11--6.90                                             0.029   2.37   0.88--6.37   0.086

CI indicates confidence interval; G+, genotype positive; HR, hazard ratio; NA, not applicable.

Items with *P*\<0.05 in univariable analyses were then included in the calculation for multivariable HR and 95% CI.

No heart transplantation occurred in genotype‐negative patients, so HR and 95% CI are not available.

Effect of Multiple Variants {#jah33489-sec-0018}
---------------------------

Because only 1 of the 17 children carried \>1 variant, the effect of multiple variants on phenotype was analyzed only in adults, of whom 6 were carriers of multiple variants. All of these 6 patients carried at least 1 variant in sarcomere genes. There was no significant difference in baseline characteristics or incidence of end points between carriers of multiple variants and single variant, except for a younger age at onset observed in the latter (Table [5](#jah33489-tbl-0005){ref-type="table"}). Univariable and multivariable Cox regression analyses showed that the risk of primary end point was significantly higher in carriers of single variant than noncarriers (hazard ratio, 2.45; 95% confidence interval, 1.08--5.54; *P*=0.032; Table [6](#jah33489-tbl-0006){ref-type="table"}). No other significant association was observed among carriers of multiple variants, single variant, and noncarriers.

###### 

Baseline Characteristics of Carriers of Multiple Variants and a Single Variant Among Adult Patients

  Characteristic                            Adult Patients (n=83)                       
  ----------------------------------------- ----------------------- ------------------- -------
  Age at enrollment, y                      42.5 (35.0--46.5)       55.0 (39.8--63.3)   0.069
  Age at onset, y                           38.5 (29.5--44.0)       52.5 (39.5--61.3)   0.033
  Male sex, n (%)                           18 (69.2)               4 (66.7)            1.000
  Family history of cardiomyopathy, n (%)   8 (30.8)                1 (16.7)            0.648
  NYHA class III/IV, n (%)                  14 (53.8)               3 (50.0)            1.000
  Comorbidities, n (%)                                                                  
  Coronary artery disease                   1 (3.8)                 0 (0.0)             1.000
  Hypertension                              0 (0.0)                 0 (0.0)             
  Diabetes mellitus                         2 (7.7)                 1 (16.7)            0.476
  Hyperlipidemia                            4 (15.4)                2 (33.3)            0.310
  Other cardiomyopathies                    9 (34.6)                2 (33.3)            1.000
  Atrial fibrillation                       9 (34.6)                2 (33.3)            1.000
  Echocardiography                                                                      
  LVEDD, mm                                 66.5 (56.3--72.0)       58.5 (47.8--63.5)   0.119
  LAD, mm                                   43.5 (38.0--50.3)       45.0 (35.3--50.3)   0.981
  LVEF, %                                   30.5 (24.8--41.8)       41.5 (34.8--50.8)   0.087
  Primary end point                                                                     
  Death and heart transplantation           13 (50.0)               3 (50.0)            1.000
  Secondary end point                                                                   
  All‐cause death                           9 (34.6)                3 (50.0)            0.647
  Sudden cardiac death                      1 (3.8)                 0 (0.0)             1.000
  Heart failure--related death              8 (30.8)                3 (50.0)            0.390
  Cardiovascular death                      9 (34.6)                3 (50.0)            0.647
  Heart transplantation                     4 (15.4)                0 (0.0)             0.566

Data are given as median (interquartile range) unless otherwise indicated. LAD indicates left atrial diameter; LVEDD, left ventricular end‐diastolic dimension; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.

###### 

Univariable and Multivariable Analyses of Association Between Number of Detected Variants and Clinical Outcomes

  Variable                          Univariable                                 Multivariable[a](#jah33489-note-0011){ref-type="fn"}                               
  --------------------------------- ------------------------------------------- ------------------------------------------------------ ------- ------ ------------ -------
  Multiple vs single variant                                                                                                                                       
  Death and heart transplantation   1.27                                        0.36--4.47                                             0.710   ···    ···          ···
  All‐cause death                   0.89                                        0.24--3.29                                             0.860   ···    ···          ···
  Heart transplantation             NA[b](#jah33489-note-0012){ref-type="fn"}   NA                                                     NA      ···    ···          ···
  Cardiovascular death              0.89                                        0.24--3.29                                             0.860   ···    ···          ···
  Sudden cardiac death              NA[c](#jah33489-note-0013){ref-type="fn"}   NA                                                     NA      ···    ···          ···
  Heart failure--related death      0.80                                        0.21--3.04                                             0.748   ···    ···          ···
  Single vs no variant                                                                                                                                             
  Death and heart transplantation   2.70                                        1.23--5.94                                             0.013   2.45   1.08--5.54   0.032
  All‐cause death                   1.87                                        0.79--4.46                                             0.156   ···    ···          ···
  Heart transplantation             NA                                          NA                                                     NA      ···    ···          ···
  Cardiovascular death              1.87                                        0.79--4.46                                             0.156   ···    ···          ···
  Sudden cardiac death              0.78                                        0.08--7.55                                             0.833   ···    ···          ···
  Heart failure--related death      2.56                                        0.96--6.86                                             0.061   ···    ···          ···
  Multiple vs no variant                                                                                                                                           
  Death and heart transplantation   2.34                                        0.65--8.41                                             0.191   ···    ···          ···
  All‐cause death                   2.34                                        0.65--8.41                                             0.191   ···    ···          ···
  Heart transplantation             NA                                          NA                                                     NA      ···    ···          ···
  Cardiovascular death              2.34                                        0.65--8.41                                             0.191   ···    ···          ···
  Sudden cardiac death              NA                                          NA                                                     NA      ···    ···          ···
  Heart failure--related death      3.73                                        0.96--14.45                                            0.057   ···    ···          ···

CI indicates confidence interval; HR, hazard ratio; NA, not applicable.

Items with *P*\<0.05 in univariable analyses were then included in the calculation of multivariable HR and 95% CI.

No heart transplantation occurred in multiple variant carriers or noncarriers, so HR and 95% CI are not available.

No sudden cardiac death occurred in multiple variant carriers, so HR and 95% CI that refer to this group are not available.

Discussion {#jah33489-sec-0019}
==========

In a large cohort of Chinese patients with LVNC, the genetic profile and correlations among genetics, clinical presentation, and long‐term outcomes were comprehensively investigated. We found that 38% of the patients carried at least one pathogenic variant, with *TTN*,*MYH7*,*MYBPC3*, and *DSP* being the most commonly involved genes. The genetic spectrum was similar between children and adults. In adults, G+ status was associated with a higher risk of death and HT, independent of age, sex, and cardiac function at baseline.

With the development of next‐generation sequencing, at least 21 genes, including sarcomeric, cytoskeletal, and ion channel genes, have been associated with LNVC.[4](#jah33489-bib-0004){ref-type="ref"} Genetic testing may have implications in diagnosis and family screening, so it is recommended for patients with LVNC.[19](#jah33489-bib-0019){ref-type="ref"} In accordance with a previously described yield of 35% to 40%,[4](#jah33489-bib-0004){ref-type="ref"} the overall yield of our gene panel was 38%, despite differences in patient selection and gene panel used. The yield of testing was found to be higher in children than that in adults with LVNC,[12](#jah33489-bib-0012){ref-type="ref"}, [20](#jah33489-bib-0020){ref-type="ref"} whereas it was similar between children and adults in our study. This might be explained by the rather small numbers of child patients in our study.

Our study revealed a distinct genetic spectrum in Chinese Han patients with LVNC. *TTN*,*MYH7*,*MYBPC3*, and *DSP* were the most commonly involved genes, which accounted for \>60% of all detected pathogenic variants. Despite studies being performed on different ethnicities, pathogenic variants in *MYH7* and *MYBPC3* were frequently detected in patients with LVNC and hypertrophic cardiomyopathy,[20](#jah33489-bib-0020){ref-type="ref"}, [21](#jah33489-bib-0021){ref-type="ref"}, [22](#jah33489-bib-0022){ref-type="ref"} which indicated the shared genetic basis between different types of cardiomyopathy. Notably, variants in *DSP* were relatively common in our study. *DSP* encodes a critical component of desmosome structure in the myocardium and is a well‐established causal gene of arrhythmogenic cardiomyopathy.[23](#jah33489-bib-0023){ref-type="ref"}, [24](#jah33489-bib-0024){ref-type="ref"} A truncating variant in *DSP* has been implicated in LVNC.[25](#jah33489-bib-0025){ref-type="ref"} Besides, another truncating variant in *DSP* was found to be associated with SCD in a family.[26](#jah33489-bib-0026){ref-type="ref"} In our study, 3 novel truncating variants in *DSP* were identified in 6 patients. Unexpectedly, ventricular arrythmias were observed in all of these 6 patients, suggesting a possible genotype‐phenotype correlation. Therefore, patients with LVNC with pathogenic variants in *DSP* may have a high risk of arrhythmic events and should be followed up closely.

Two novel truncating variants in *LAMP2* were identified in 2 patients in our study. Deficiency in *LAMP2* has been shown to cause an X‐linked lysosomal condition called Danon disease.[27](#jah33489-bib-0027){ref-type="ref"} The role of *LAMP2* in LVNC was only described in a case report, in which a truncating *LAMP2* variant was described as having been detected in a patient with LVNC and Danon disease.[28](#jah33489-bib-0028){ref-type="ref"} Herein, we provide additional evidence of the association between *LAMP2* deficiency and LVNC.

It is well recognized that 15% to 30% of patients with LVNC could experience premature death, and ≈10% could develop severe HF that may eventually lead to HT.[3](#jah33489-bib-0003){ref-type="ref"}, [29](#jah33489-bib-0029){ref-type="ref"} In our study, 27% of the patients died and 5% underwent HT, which also revealed the considerable morbidity and mortality in the process of LVNC. Despite the relatively poor prognosis, the effect of a positive genetic test result on long‐term outcomes remains unclear in adult patients. Probst et al found that pathogenic variants were not associated with cardiac function, HF, or arrythmia events.[30](#jah33489-bib-0030){ref-type="ref"} Similarly, a recent study by van Waning et al showed no difference in the risk of major adverse cardiac events between adults with LVNC with and without pathogenic variants.[20](#jah33489-bib-0020){ref-type="ref"} In contrast, our study found that G+ status was independently associated with higher risks of death and HT in adult patients with LVNC. More than 70 sarcomere and nonsarcomere genes were screened in our study, whereas the study by Probst et al focused mainly on sarcomere genes.[30](#jah33489-bib-0030){ref-type="ref"} The end point in the study by van Waning et al differed from ours, with thromboembolism and arrythmia events additionally being included.[20](#jah33489-bib-0020){ref-type="ref"} Besides, only 6% of participants died and 2% received HT in their study, which were much less than those in our study. Such differences in screening genes and end points might at least partially explain the difference in results between these studies and ours. Our discovery is of great importance, because prognostic implications can be speculated from genetic testing. Such information can aid in risk stratification, which can then assist with therapeutic decision making and improve prognosis.

The specific mechanism underlying the adverse outcomes of G+ patients is still unclear. A plausible one is the remarkably abnormal structure and/or function of cardiomyocytes caused by the variants. For example, a defect in sarcomere genes can lead to the development of diminished force generation and myocardial fibrosis.[13](#jah33489-bib-0013){ref-type="ref"}, [31](#jah33489-bib-0031){ref-type="ref"} These changes may eventually result in contractile dysfunction and, therefore, may be associated with higher rates of HF events. In support, of all the adult patients with variants in sarcomere genes in our study, more than half had left ventricular ejection fraction \<40% at baseline and one third died of HF during the follow‐up. Defects in genes encoding ion channels, such as *KCNE1* and *SCN5A*, have been related with disturbed currents in cardiomyocytes, which may be associated with higher risk of arrhythmic events, including SCD.[32](#jah33489-bib-0032){ref-type="ref"}, [33](#jah33489-bib-0033){ref-type="ref"}

Multiple pathogenic variants have been associated with more severe manifestations and worse outcomes in patients with LVNC, compared with a single variant.[31](#jah33489-bib-0031){ref-type="ref"}, [34](#jah33489-bib-0034){ref-type="ref"} In our study, the risk of death and HT in carriers of multiple variants was higher but not significantly than that in carriers of a single variant or noncarriers. Because there were only 6 adult patients carrying \>1 pathogenic variant, our failure to confirm a dosage effect of pathogenic variants might have been attributable to the lack of a sufficient number of participants for the results to reach a significant level.

There were several limitations in this study. First, this was an observational study, which might have been associated with an intrinsic bias. Second, all participants were from a single tertiary center. This might have caused a lack of representativeness and limited the generalizability of the findings. Third, the sample size was relatively small, so certain conclusions could not be drawn in some subgroups, such as child patients. Studies in larger populations are needed to confirm our discoveries.

To our knowledge, this is one of the largest LVNC cohorts with detailed genetic information and long‐term follow‐up data in a Chinese Han population. We proved that, in adult patients with LVNC, G+ status was an independent risk factor for death and HT, highlighting the importance of genetic testing for better risk stratification of the individual patient.
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